Literature DB >> 1329642

Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.

B B Gooding1, M E Erwin, M S Barrett, D M Johnson, R N Jones.   

Abstract

The antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) were compared with those of five similar compounds and four comparison drugs against 103 strains of Legionella pneumophila and five other Legionella species type strains. When concentrations inhibiting 90% of strains tested (MIC90s) for L. pneumophila were determined, CI-960 and temafloxacin emerged as the most active (0.015 microgram/ml) and were followed in potency by E4695 (0.03 microgram/ml). This activity was two- to fourfold greater than that of the reference drug, ciprofloxacin, and approached that of rifampin (MIC90, 0.008 microgram/ml). All fluoroquinolones studied were more active than erythromycin (MIC90, 0.5 microgram/ml). These two investigational fluoroquinolones appear well suited for further in vivo study of legionellosis therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329642      PMCID: PMC192436          DOI: 10.1128/AAC.36.9.2049

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Activity of sparfloxacin (AT-4140), PD127391 and PD131628 against Legionella spp.

Authors:  R N Jones
Journal:  J Antimicrob Chemother       Date:  1991-03       Impact factor: 5.790

2.  In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils.

Authors:  R Garraffo; D Jambou; R M Chichmanian; S Ravoire; P Lapalus
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

Authors:  R N Jones; K E Aldridge; A L Barry; P C Fuchs; E H Gerlach; M A Pfaller; J A Washington
Journal:  Diagn Microbiol Infect Dis       Date:  1988-08       Impact factor: 2.803

4.  The effect of charcoal on MICs for Legionella.

Authors:  J Barker; I D Farrell
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

5.  In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391.

Authors:  M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; C L Heifetz
Journal:  Diagn Microbiol Infect Dis       Date:  1991 May-Jun       Impact factor: 2.803

6.  Legionnaires' disease associated with a hospital water system: a cluster of 24 nosocomial cases.

Authors:  C M Helms; R M Massanari; R Zeitler; S Streed; M J Gilchrist; N Hall; W J Hausler; J Sywassink; W Johnson; L Wintermeyer; W J Hierholzer
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

7.  In vitro evaluation of E-4695, a new fluoro-naphthyridine.

Authors:  R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

8.  Uptake of ciprofloxacin by human neutrophils.

Authors:  C S Easmon; J P Crane
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

9.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

10.  Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila.

Authors:  D Havlichek; L Saravolatz; D Pohlod
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

  10 in total
  5 in total

Review 1.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1993       Impact factor: 9.546

2.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

3.  In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella.

Authors:  S J Martin; S L Pendland; C Chen; P Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Limited effects of temafloxacin compared with ciprofloxacin on T-lymphocyte function.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 5.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.